Asian Journal of Pharmaceutical and Clinical Research,
Journal Year:
2025,
Volume and Issue:
unknown, P. 8 - 26
Published: Feb. 7, 2025
Hepatocellular
carcinoma
(HCC)
represents
a
significant
threat
to
global
health
and
is
responsible
for
mortality
rates
worldwide.
Conventional
treatment
options
such
as
surgery
chemotherapy
have
inherent
limitations.
In
order
remedy
these
deficits,
the
development
of
novel
therapeutic
strategies
essential.
Nanomedicines
shown
promise
in
HCC
they
offer
improved
stability,
controlled
release,
increased
drug
loading
capacity.
This
review
explores
application
nanoconstructs
treatment,
including
active
passive
targeting
strategies.
addition,
liver
cell
approaches,
moieties,
conjugation
chemistry
surface
functionalization
are
investigated.
A
compact
overview
various
approaches
also
given.
Nano Convergence,
Journal Year:
2021,
Volume and Issue:
8(1)
Published: Nov. 2, 2021
Modern
medicine
has
been
waging
a
war
on
cancer
for
nearly
century
with
no
tangible
end
in
sight.
Cancer
treatments
have
significantly
progressed,
but
the
need
to
increase
specificity
and
decrease
systemic
toxicities
remains.
Early
diagnosis
holds
key
improving
prognostic
outlook
patient
quality
of
life,
diagnostic
tools
are
cusp
technological
revolution.
Nanotechnology
steadily
expanded
into
reaches
chemotherapy,
radiotherapy,
diagnostics,
imaging,
demonstrating
capacity
augment
each
advance
care.
Nanomaterials
provide
an
abundance
versatility,
functionality,
applications
engineer
specifically
targeted
medicine,
accurate
early-detection
devices,
robust
imaging
modalities,
enhanced
radiotherapy
adjuvants.
This
review
provides
insights
current
clinical
pre-clinical
nanotechnological
drug
therapy,
radiation
therapy.
Acta Pharmaceutica Sinica B,
Journal Year:
2021,
Volume and Issue:
12(1), P. 378 - 393
Published: June 18, 2021
The
immune
checkpoint
blockade
therapy
has
profoundly
revolutionized
the
field
of
cancer
immunotherapy.
However,
despite
great
promise
for
a
variety
cancers,
efficacy
inhibitors
is
still
low
in
colorectal
(CRC).
This
mainly
due
to
immunosuppressive
feature
tumor
microenvironment
(TME).
Emerging
evidence
reveals
that
certain
chemotherapeutic
drugs
induce
immunogenic
cell
death
(ICD),
demonstrating
potential
remodeling
TME.
In
this
study,
ginsenoside
Rg3
(Rg3)
as
an
ICD
inducer
against
CRC
cells
was
confirmed
using
Science Advances,
Journal Year:
2023,
Volume and Issue:
9(29)
Published: July 19, 2023
The
polarization
of
tumor-associated
macrophages
(TAMs)
from
M2
to
M1
phenotype
demonstrates
great
potential
for
remodeling
the
immunosuppressive
tumor
microenvironment
(TME)
hepatocellular
carcinoma
(HCC).
d-lactate
(DL;
a
gut
microbiome
metabolite)
acts
as
an
endogenous
immunomodulatory
agent
that
enhances
Kupffer
cells
clearance
pathogens.
In
this
study,
DL
transformation
TAMs
was
confirmed,
and
mechanisms
underlying
such
were
mainly
due
modulation
phosphatidylinositol
3-kinase/protein
kinase
B
pathway.
A
poly(lactide-co-glycolide)
nanoparticle
(NP)
used
load
DL,
DL-loaded
NP
modified
with
HCC
membrane
macrophage-binding
peptide
(M2pep),
forming
nanoformulation
(DL@NP-M-M2pep).
DL@NP-M-M2pep
transformed
remodeled
TME
in
mice,
promoting
efficacy
anti-CD47
antibody
long-term
animal
survival.
These
findings
reveal
TAM
modulatory
function
provide
combinatorial
strategy
immunotherapy.
Signal Transduction and Targeted Therapy,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: Aug. 12, 2024
Cancer
remains
a
significant
risk
to
human
health.
Nanomedicine
is
new
multidisciplinary
field
that
garnering
lot
of
interest
and
investigation.
shows
great
potential
for
cancer
diagnosis
treatment.
Specifically
engineered
nanoparticles
can
be
employed
as
contrast
agents
in
diagnostics
enable
high
sensitivity
high-resolution
tumor
detection
by
imaging
examinations.
Novel
approaches
labeling
are
also
made
possible
the
use
nanoprobes
nanobiosensors.
The
achievement
targeted
medication
delivery
therapy
accomplished
through
rational
design
manufacture
nanodrug
carriers.
Nanoparticles
have
capability
effectively
transport
medications
or
gene
fragments
tissues
via
passive
active
targeting
processes,
thus
enhancing
treatment
outcomes
while
minimizing
harm
healthy
tissues.
Simultaneously,
context
radiation
sensitization
photothermal
enhance
therapeutic
efficacy
malignant
tumors.
This
review
presents
literature
overview
summary
how
nanotechnology
used
According
oncological
diseases
originating
from
different
systems
body
combining
pathophysiological
features
cancers
at
sites,
we
most
recent
developments
applications.
Finally,
briefly
discuss
prospects
challenges
cancer.
Frontiers in Pharmacology,
Journal Year:
2023,
Volume and Issue:
14
Published: April 21, 2023
As
traditional
strategies
for
cancer
treatment,
some
chemotherapy
agents,
such
as
doxorubicin,
oxaliplatin,
cyclophosphamide,
bortezomib,
and
paclitaxel
exert
their
anti-tumor
effects
by
inducing
immunogenic
cell
death
(ICD)
of
tumor
cells.
ICD
induces
immunity
through
release
of,
or
exposure
to,
damage-related
molecular
patterns
(DAMPs),
including
high
mobility
group
box
1
(HMGB1),
calreticulin,
adenosine
triphosphate,
heat
shock
proteins.
This
leads
to
activation
tumor-specific
immune
responses,
which
can
act
in
combination
with
the
direct
killing
functions
drugs
on
cells
further
improve
curative
effects.
In
this
review,
we
highlight
mechanisms
underlying
ICD,
those
several
chemotherapeutic
DAMPs
exposed
during
activate
system,
well
discussing
prospects
application
potential
role
immunotherapy,
aim
providing
valuable
inspiration
future
development
chemoimmunotherapy.
Small Methods,
Journal Year:
2023,
Volume and Issue:
7(5)
Published: Jan. 5, 2023
Immunogenic
cell
death
(ICD,
also
known
as
immunogenic
apoptosis)
of
malignant
cells
is
confirmed
to
activate
the
host
immune
system
prevent,
control,
and
eliminate
tumors.
Recently,
a
range
chemotherapeutic
drugs
have
been
repurposed
ICD
inducers
applied
for
tumor
immunotherapy.
However,
several
hurdles
widespread
application
remain,
namely
poor
water
solubility,
short
blood
circulation,
non-specific
tissue
distribution,
severe
toxicity.
Recent
advances
in
nanotechnology
pharmaceutical
formulation
foster
development
nano
drug
delivery
systems
tackle
aforementioned
expedite
safe,
effective,
specific
delivery.
This
review
will
describe
barriers
chemical
highlight
recent
nanoformulations
these
MedComm,
Journal Year:
2024,
Volume and Issue:
5(4)
Published: April 1, 2024
Abstract
Reactive
oxygen
species
(ROS)
constitute
a
spectrum
of
oxygenic
metabolites
crucial
in
modulating
pathological
organism
functions.
Disruptions
ROS
equilibrium
span
various
diseases,
and
current
insights
suggest
dual
role
for
tumorigenesis
the
immune
response
within
cancer.
This
review
rigorously
examines
production
its
normal
cells,
elucidating
subsequent
regulatory
network
inflammation
Comprehensive
synthesis
details
documented
impacts
on
diverse
cells.
Exploring
intricate
relationship
between
cancer
immunity,
we
highlight
influence
existing
immunotherapies,
including
checkpoint
blockade,
chimeric
antigen
receptors,
vaccines.
Additionally,
underscore
promising
prospects
utilizing
targeting
modulators
as
novel
immunotherapeutic
interventions
discusses
complex
interplay
ROS,
inflammation,
tumorigenesis,
emphasizing
multifaceted
functions
both
physiological
conditions.
It
also
underscores
potential
implications
immunotherapy
suggests
future
research
directions,
development
targeted
therapies
precision
oncology
approaches.
In
summary,
this
emphasizes
significance
understanding
ROS‐mediated
mechanisms
advancing
therapy
developing
personalized
treatments.
Chemical Society Reviews,
Journal Year:
2024,
Volume and Issue:
53(12), P. 6399 - 6444
Published: Jan. 1, 2024
This
review
highlights
recent
advances
in
immunological
nanomaterials
against
metastasis
and
summarizes
various
nanomaterial-mediated
immunotherapy
strategies.
Cell Death and Disease,
Journal Year:
2025,
Volume and Issue:
16(1)
Published: Feb. 7, 2025
Abstract
Gastric
cancer
(GC)
remains
a
leading
cause
of
cancer-related
mortality
worldwide,
with
limited
treatment
options
in
advanced
stages.
Immunotherapy,
particularly
immune
checkpoint
inhibitors
(ICIs)
targeting
PD1/PD-L1,
has
emerged
as
promising
therapeutic
approach.
However,
significant
proportion
patients
exhibit
primary
or
acquired
resistance,
limiting
the
overall
efficacy
immunotherapy.
This
review
provides
comprehensive
analysis
mechanisms
underlying
immunotherapy
resistance
GC,
including
role
tumor
microenvironment,
dynamic
PD-L1
expression,
compensatory
activation
other
checkpoints,
and
genomic
instability.
Furthermore,
explores
GC-specific
factors
such
molecular
subtypes,
unique
evasion
mechanisms,
impact
Helicobacter
pylori
infection.
We
also
discuss
emerging
strategies
to
overcome
combination
therapies,
novel
immunotherapeutic
approaches,
personalized
based
on
genomics
microenvironment.
By
highlighting
these
key
areas,
this
aims
inform
future
research
directions
clinical
practice,
ultimately
improving
outcomes
for
GC
undergoing